Autonomix Medical raises $4.9M via warrant inducement agreement

Autonomix Medical, Inc. (NASDAQ: AMIX) announced a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants originally issued on July 15, 2026.

Under the agreement, the investor will exercise warrants to purchase 857,462 shares of common stock at $5.75 per share. Gross proceeds are expected to total approximately $4.9 million, before financial advisory fees and offering expenses. The transaction is expected to close on or about August 26, 2026, subject to customary closing conditions.

In exchange for the immediate cash exercise of the existing warrants, Autonomix agreed to issue new unregistered Series E-1 and Series E-2 warrants, each covering 535,913 shares of common stock, for a combined total of 1,071,826 shares. The new warrants carry an exercise price of $6.25 per share, are exercisable upon issuance, and expire five years from the date of issuance. Autonomix stated it will file a registration statement with the Securities and Exchange Commission covering the resale of shares issuable upon exercise of the new warrants.

The new warrants are being offered in a private placement under an exemption from the registration requirements of the Securities Act of 1933 and have not been registered with the SEC.

Maxim Group LLC served as warrant inducement agent and financial advisor for the transaction.

The information above is based on a press release issued by Autonomix Medical.

You May Also Be Interested In

• Southern Cross Acquisition II prices $75M IPO on Nasdaq
• Maison Solutions gets Nasdaq notice over late 10-K filing
• YY Group cancels $5.94M note tranche and all outstanding warrants